Business ❯ Pharmaceutical Industry ❯ Market Trends

Drug Pricing

Novo Nordisk Generic Competition Insurance Coverage Insulin Manufacturing Cost of Medications Consumer Access Generic Medications Valuation Metrics Economic Impact Eli Lilly and Novo Nordisk Obesity Medications Investment Alternative Medications Revenue Projections

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Lilly’s premium price meets a new oral challenger in the GLP‑1 race.

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Blog Jobs Terms of Service Privacy Policy Cookies Help Partners About Us Copyright © 2026 Mina Labs, Inc.

We value your privacy

We and our partners use cookies and similar technologies to understand how you use our site and to show you personalized advertisements on other platforms. By clicking "Accept All," you consent to these technologies for advertising, analytics and retargeting. Click "Decline All" to opt out of non-essential cookies. You can learn more in our Privacy Policy.